BNET Industries
Market Cap:$143.3B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
CORRECTING and REPLACING Pfizer And Crown Bioscience Announce A Collaboration To Research And...
-
Research and Markets: The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to...
-
Science and Technology: Pfizer to buy Croatian drug patent
-
Bristol-Myers Squibb Raises Exchange Offer Price For Mead Johnson Shares - Update
-
'IT boosts efficiency & innovation'
-
Inspector General Saved Billions in Healthcare This Year
-
Pfizer and B.C. launch $9M collaboration to tackle cancer
-
Reportlinker Adds Growth Factors Blood And Tissue - A World Report
-
Pfizer signs agreement with Protalix BioTherapeutics for Taliglucerase alfa
-
Pfizer Inc. PFE JOBS Acquires Rights to Protalix Biotherapeutics's Gaucher Drug in Deal Worth $115M
-
Conservationists salute two corporations
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
2009: The Year That Was For Pfizer
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
-
Standpoint Raised Its FY10 Price Target on Pfizer PFE to $24
-
ImmunoVaccine signs exclusive licence deal with Pfizer
-
Pfizer Animal Health selects Bader Rutter as agency of record
News & Analysis
Filter by
derek lowe and pfizer inc. - All News and Analysis
Pfizer's Chemistry Head Count: Lower than Before the Wyeth Merger
Seeking Alpha
- 2009-11-11
Derek Lowe submits: A reader who's unfortunately in a position to know the details sends along some numbers on Pfizer's PFE chemistry shakeout. According to his figures, Pfizer (pre-Wyeth merger) had about 900 chemists. The Wyeth deal brought in about 350, but no one expected the merged department to...
Pfizer's New Look
Seeking Alpha
- 2009-11-10
Derek Lowe submits: The company has issued a press release detailing which sites are staying, and which are leaving: Pfizer PFE will have five main research sites that will serve as central hubs for research activities in BioTherapeutics, PharmaTherapeutics and Vaccines. These sites are: Cambridge, Mass.;...
Another Look at Pfizer's Recent Moves
Seeking Alpha
- 2009-11-10
Derek Lowe submits: Pharmaconduct.org has another look at Pfizer's PFE announcement Monday, and tries to address some of the many unanswered questions left open by the company's press release. One thing that struck me and many others is that the company talked about "moving a number of functions" from...
Pfizer's People Aren't to Blame
Seeking Alpha
- 2009-10-22
Derek Lowe submits: I wanted to highlight a comment that showed up recently in the latest Pfizer PFE post: I would just like to point out that there is often mention of Pfizer as being a poorly productive R&D outfit on this blog, but there is...
Pfizer: What It Will Look Like a Year from Now
Seeking Alpha
- 2009-10-20
Derek Lowe submits: The Wall Street Journal's Health Blog got a chance to ask the higher-ups at Pfizer PFE what their R&D will look like a year from now. Their understandably not too-in-depth answers are here: Decentralized research units, with some functions run company-wide, and this quote: "There are...
Which Pfizer / Wyeth Sites Will Shut Down?
Seeking Alpha
- 2009-09-28
Derek Lowe submits: I have no solid information on this question myself, but Eric Milgram over at Pharmaconduct is trying a wisdom-of-crowds approach. He's got a survey up of which sites people think will close, and it'll be interesting to see how well this matches up with the eventual...
Big Pharma's Future Death Spiral?
Seeking Alpha
- 2009-09-18
Derek Lowe submits: One of this blog's regular correspondents has just been attending a chemistry outsourcing conference program here, and heard a very interesting talk from Stefan Loren of a Baltimore investment advisory firm, Westwicke Partners. Loren's a product of the Sharpless lab, who went on to Abbott ABT,...
Pfizer Whistle-Blowing: The How and Why
Seeking Alpha
- 2009-09-06
Derek Lowe submits: Here's more detail on the case that led to Pfizer's PFE 2.3 billion dollar fine/settlement, courtesy of Bloomberg. Here's how things got started, apparently: Pfizer Inc. sales folks had one tough customer in psychiatrist Stefan Kruszewski. He didn’t buy their pitch to prescribe...
Justice Department Makes 2.3 Billion Dollar Example of Pfizer's Marketing Practices
Seeking Alpha
- 2009-09-03
Derek Lowe submits: No sooner do I write another post about pharma marketing than Pfizer PFE finds itself paying 3.2 billion dollars in fines for doing it improperly. 1.2 billion of that is a criminal penalty, and needless to say, they've set the current record. The...
A View from Pfizer's Corner Offices
Seeking Alpha
- 2009-06-18
Derek Lowe submits: There's a good article from Lee Howard up at The Day (the New London/Groton newspaper) on the changes going on at Pfizer. It's the story according to management, though, which is worth having for its compare-and-contrast uses: Despite the looming uncertainty, according to company...
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
Presented by the Premiere Rewards Gold Card from American Express